Would ivermectin for malaria control be beneficial in onchocerciasis-endemic regions?

作     者：Joseph Nelson Siewe Fodjo Marina Kugler An Hotterbeekx Adam Hendy Jean-Pierre Van Geertruyden Robert Colebunders 

作者机构：Global Health InstituteUniversity of AntwerpKinsbergen centrumDoornstraat 3312610 AntwerpBelgium 不详 

出 版 物：《Infectious Diseases of Poverty》 (贫困所致传染病（英文）)

年 卷 期：2019年第8卷第4期

页      面：108-108页

核心收录：

学科分类：1002[医学-临床医学] 100201[医学-内科学(含：心血管病、血液病、呼吸系病、消化系病、内分泌与代谢病、肾病、风湿病、传染病)] 10[医学] 

基　　金：Horizon 2020 Framework Programme, H2020, (671055) European Research Council, ERC 

主　　题：Malaria Ivermectin Onchocerciasis Mass drug administration Vector control 

摘      要：Background:There is accumulating evidence supporting the use of ivermectin as a malaria control *** findings from the repeat ivermectin mass drug administrations for control of malaria trial demonstrated a reduced incidence of malaria in villages which received repeated ivermectin mass drug administration(MDA;six doses)compared to those who had only one round of *** other studies investigating the benefits of ivermectin for malaria purposes are ongoing/*** text:While ivermectin MDA offers promising perspectives in the fight against malaria,we highlight the added benefits and anticipated challenges of conducting future studies in onchocerciasis-endemic regions,which are confronted with a substantial disease burden including onchocerciasis-associated *** the frequency of ivermectin MDA in such places may reduce the burden of both malaria and onchocerciasis,and allow for more entomological investigations on both the Anopheles mosquitoes and the ***,acceptability and feasibility studies are needed to assess the endorsement by the local populations,as well as the programmatic feasibility of implementing ivermectin MDA several times a ***:Onchocerciasis-endemic sites would doubly benefit from ivermectin MDA interventions,as these will alleviate onchocerciasis-associated morbidity and mortality,while potentially curbing malaria *** onchocerciasis programs and other relevant stakeholders in the malaria/ivermectin research agenda would foster the implementation of pluri-annual MDA in target communities.